ANDA 211861, held by Prinston Pharmaceutical. Amphetamine Sulfate.
As of Nov 21, 2026, ANDA 211861 (Amphetamine Sulfate), held by Prinston Pharmaceutical, was first approved by FDA on Mar 11, 2020, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amphetamine sulfate tablets, USP, are indicated for: 1. Narcolepsy 2. Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2020 | Original application | Approved | None posted |
| Amphetamine Sulfate5MG · tablet;oral | Amphetamine Sulfate | Rx |
| Amphetamine Sulfate10MG · tablet;oral | Amphetamine Sulfate | Rx |
| Oct 18, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 17, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 11, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters